NBGUX
Price
$31.85
Change
-$0.02 (-0.06%)
Updated
Sep 12 closing price
Net Assets
2.64B
RGEBX
Price
$83.86
Change
-$0.14 (-0.17%)
Updated
Sep 12 closing price
Net Assets
335.91B
Interact to see
Advertisement

NBGUX vs RGEBX

Header iconNBGUX vs RGEBX Comparison
Open Charts NBGUX vs RGEBXBanner chart's image
Neuberger Berman Large Cap Growth Adv
Price$31.85
Change-$0.02 (-0.06%)
VolumeN/A
Net Assets2.64B
American Funds Growth Fund of Amer R2E
Price$83.86
Change-$0.14 (-0.17%)
VolumeN/A
Net Assets335.91B
NBGUX vs RGEBX Comparison Chart in %
Loading...
View a ticker or compare two or three
VS
NBGUX vs. RGEBX commentary
Sep 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NBGUX is a StrongBuy and RGEBX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RGEBX has more cash in the bank: 336B vs. NBGUX (2.64B). NBGUX (0.00) and RGEBX (0.00) have matching dividends . NBGUX was incepted earlier than RGEBX: NBGUX (29 years) vs RGEBX (11 years). NBGUX (1.44) is less costly to investors than RGEBX (1.09). NBGUX is a more actively managed with annual turnover of: 30.00 vs. RGEBX (25.00). NBGUX has a lower initial minimum investment than RGEBX: NBGUX (0) vs RGEBX (250). RGEBX annual gain was more profitable for investors over the last year : 17.04 vs. NBGUX (12.94). RGEBX (45.42) and NBGUX (44.17) have equivalent 5 years return.
NBGUXRGEBXNBGUX / RGEBX
Total Expense Ratio1.441.09132%
Annual Report Gross Expense Ratio1.441.09132%
Fund Existence29 years11 years-
Gain YTD12.58417.38572%
Front LoadN/AN/A-
Min. Initial Investment0250-
Min. Initial Investment IRAN/AN/A-
Net Assets2.64B336B1%
Annual Yield % from dividends0.000.00-
Returns for 1 year12.9417.0476%
Returns for 3 years48.6257.6584%
Returns for 5 years44.1745.4297%
Returns for 10 years76.0993.7981%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LMOPX41.490.21
+0.51%
Patient Opportunity C
GGRCX16.830.05
+0.30%
Goldman Sachs Strategic Growth C
GTECX48.790.03
+0.06%
Gateway C
AWSIX17.87-0.06
-0.33%
Invesco Global Core Equity R5
BGGSX31.23-0.23
-0.73%
Baillie Gifford US Equity Growth I